CClinicalTrials.gg
Active, not recruitingNCT07283614HYP-RRDUpdated Mar 18, 2026

Ocular Hypotony and Refractive Predictability in RRD Surgery

An interventional study of Combined Phacovitrectomy with Intraocular Lens Implantation and Silicone Oil Tamponade and Silicone Oil Removal in Rhegmatogenous Retinal Detachment and Hypotony Ocular, sponsored by Kazakh Eye Research Institute. Active, not recruiting at 1 site in Kazakhstan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Kazakh Eye Research Institute · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates how preoperative ocular hypotony (Goldmann IOP ≤ 7 mmHg) affects refractive predictability, axial length measurements, and visual outcomes in patients undergoing combined phacovitrectomy with silicone oil for rhegmatogenous retinal detachment.

Read the detailed description

This observational cohort study is designed to evaluate the impact of preoperative ocular hypotony (defined as Goldmann IOP ≤ 7 mmHg) on refractive outcomes, biometry parameters, and visual acuity after combined phacovitrectomy for RRD. All included eyes undergo standard 25-gauge pars plana vitrectomy with cataract extraction with IOL implantation, endolaser photocoagulation, and silicone oil tamponade.

The study population consists of eyes with primary RRD and stratified into two cohorts according to preoperative IOP:

Hypotony group - eyes with Goldmann IOP ≤ 7 mmHg; Control group - eyes with normal preoperative IOP .

02

Conditions studied

  • Rhegmatogenous Retinal Detachment
  • Hypotony Ocular

Keywords

  • Rhegmatogenous Retinal Detachment
  • Hypotony Ocular
  • cataract surgery
  • intraocular lens calculation
  • refractive assessment
  • vitreoretinal surgery
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of primary rhegmatogenous retinal detachment (RRD)
  • Single-stage combined phacovitrectomy with clear corneal phacoemulsification with IOL implantation and 25G pars plana vitrectomy with silicone oil tamponade in the study eye
  • Preoperative intraocular pressure (IOP) in the study eye measured by Goldmann applanation tonometry: Hypotony group: IOP ≤ 7 mmHg; Normotony group: IOP > 7 mmHg
  • Planned silicone oil removal approximately 3 months after the initial combined surgery and ability to attend follow-up for refractive assessment 1 month after silicone oil removal
  • Age (e.g., ≥18 years) and ability to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Previous intraocular surgery in the study eye
  • Secondary or complex RRD associated with ocular trauma, uveitis or other active intraocular inflammation, proliferative diabetic retinopathy or other advanced vascular retinopathies, significant ocular malformations or congenital anomalies of the globe or posterior segment, pre-existing advanced glaucoma or uncontrolled ocular hypertension, or other optic nerve pathology that could confound visual and refractive outcomes, corneal opacity, significant corneal irregularity, or media opacity precluding reliable biometry or accurate axial length measurement in the study eye, systemic diseases or autoimmune conditions with known ocular involvement that may affect the retina, choroid, or refraction
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    RRD Patients with Ocular Hypotony

    Patients with primary rhegmatogenous retinal detachment (RRD) and preoperative ocular hypotony, defined as Goldmann intraocular pressure (IOP) ≤ 7 mmHg, undergoing combined phacoemulsification and IOL implantation, pars plana vitrectomy with silicone oil tamponade. Silicone oil is planned to be removed approximately 3 months after the initial combined surgery and detailed refractive assessment is performed 1 month after silicone oil removal. This cohort is used to evaluate the impact of preoperative hypotony on axial length measurements, refractive predictability (MAE, % within ±0.50 D), and visual outcomes.

    Procedure: Combined Phacovitrectomy with Intraocular Lens Implantation and Silicone Oil Tamponade · Procedure: Silicone Oil Removal

  • Active comparator
    RRD patients with normal IOP

    Patients with primary rhegmatogenous retinal detachment (RRD) and normal preoperative IOP (\> 7 mmHg) undergoing the same combined phacovitrectomy with IOL implantation and silicone oil tamponade. Silicone oil is planned to be removed approximately 3 months after the initial combined surgery and detailed refractive assessment is performed 1 month after silicone oil removal. This cohort serves as the comparison group for the hypotony arm to determine whether normal preoperative IOP is associated with more accurate axial length measurements, better refractive predictability, and comparable or superior visual outcomes.

    Procedure: Combined Phacovitrectomy with Intraocular Lens Implantation and Silicone Oil Tamponade · Procedure: Silicone Oil Removal

Interventions

  • ProcedureCombined Phacovitrectomy with Intraocular Lens Implantation and Silicone Oil Tamponade

    Standardized single-stage clear corneal phacoemulsification with IOL implantation is combined with three-port 25-gauge pars plana vitrectomy, fluid-air exchange, endolaser photocoagulation, and silicone oil tamponade for rhegmatogenous retinal detachment. After cataract extraction and IOL placement, pars plana vitrectomy is performed with fluid-air exchange to reattach the retina, endolaser photocoagulation around retinal breaks, and tamponade with silicone oil.

  • ProcedureSilicone Oil Removal

    Silicone oil removal is performed approximately 3 months after the initial combined phacovitrectomy. Three-port 25-gauge pars plana access and pressure-controlled fluid-silicone exchange with balanced salt solution to completely remove silicone oil from the vitreous cavity. At the end of surgery, sclerotomies are sutured.

05

What researchers measure

Primary outcomes

  1. Mean Absolute Error (MAE) of Postoperative Refraction

    Mean Absolute Error between the target refraction predicted by preoperative IOL power calculation and the achieved postoperative spherical equivalent refraction, calculated in diopters for each eye. Percentage of eyes in each group with an Mean Absolute Error ≤ ±0.50 diopters between the target refraction and the achieved postoperative spherical equivalent refraction.

    Time frame: 1 month after silicone oil removal

Secondary outcomes

  1. Axial Length Measurement

    Difference between preoperative and postoperative axial length measurements, and its correlation with preoperative IOP status.

    Time frame: 1 month after silicone oil removal

  2. Best-Corrected Visual Acuity

    Best-Corrected Visual Acuity measured in Logarithm of the Minimum Angle of Resolution (LogMAR) units using standard visual acuity charts and compared between hypotony and normotony groups after surgery and silicone oil removal

    Time frame: 3 months after combined surgery, 1 month after silicone oil removal

06

Study locations

1 site
  • Kazakh Eye Research Institute
    Almaty, 050012, Kazakhstan
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07283614
Lead sponsor
Kazakh Eye Research Institute
Responsible party
Kairat Ruslanuly (Principal Investigator, Kazakh Eye Research Institute) — Principal investigator
First posted
Dec 16, 2025
Start date
Dec 8, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Oct 17, 2026 (estimated)
Last update
Mar 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion